



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

StockExchange-NSE letters/MM:SA:673

June 1, 2017

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Financial Results of the Company for the Quarter\Year ended March 2017

The Company has recieved e-mail dated May 31, 2017 from BSE Ltd. with respect to Consolidated statement of Assets & Liabilities not tallying for the year ended March 31, 2017, submitted by the Company on May 23, 2017. Enclosed please find:

1. Standalone audited financial results for the year ended on March 31, 2017 alongwith Auditor's Report.
2. Consolidated audited financial results for the year ended on March 31, 2017 alongwith Auditor's Report, with the note on asstes and liabilities duly corrected.

We request you to take the above on record.

Thranking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary and Vice President - Compliance

📍 **Registered Office:**

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**

Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2017

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2017	31-12-2016	31-03-2016	31-03-2017	31-03-2016	31-03-2017	31-03-2016
		Audited (refer note 7)	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	30,626.19	27,648.17	30,275.91	1,19,869.42	1,16,493.57	1,36,831.70	1,23,158.31
2	Other Income	1,276.27	769.05	2,005.14	4,589.03	5,567.60	5,015.70	5,665.36
3	Total Income (1+2)	31,902.46	28,417.22	32,281.05	1,24,458.45	1,22,061.17	1,41,847.40	1,28,823.67
4	Expenses							
	a. Cost of materials consumed	9,131.39	8,230.94	8,967.58	36,709.36	37,307.84	36,709.36	37,307.84
	b. Purchases of stock-in-trade	2,857.52	2,320.23	2,868.96	9,624.47	8,254.88	15,244.24	11,062.85
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(663.24)	(276.94)	(698.68)	(1,805.26)	(684.05)	843.13	(1,351.43)
	d. Employees benefits expense	4,989.62	4,702.63	4,671.16	18,786.11	16,595.97	20,654.37	17,530.68
	e. Finance Costs	(24.05)	243.00	209.80	500.13	1,029.48	537.16	1,064.59
	f. Depreciation and amortization expense	1,240.46	1,135.96	1,037.31	4,626.42	4,040.87	4,722.44	4,122.23
	g. Other Expenses	9,623.41	8,097.60	8,896.53	34,338.86	32,446.84	40,142.29	38,005.28
	Total Expenses (4)	27,155.11	24,453.42	25,952.66	1,02,780.09	98,991.83	1,18,852.99	1,07,742.04
5	Profit before Tax and share of joint venture (3-4)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,081.63
6	Share of Profit of joint venture	-	-	-	-	-	-	141.47
7	Profit before Tax (5+6)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,223.10
8	Tax expenses	532.44	387.70	1,274.79	4,381.90	5,149.05	4,554.59	4,958.04
9	Net Profit/(Loss) after Tax before non controlling interest(7-8)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,439.82	16,265.05
10	Non controlling interest	-	-	-	-	-	33.55	10.40
11	Net Profit/(Loss) after Tax and non controlling Interest (9-10)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,406.27	16,254.65
12	Other Comprehensive Income (net of Tax)	(246.21)	(8.08)	(7.75)	(270.43)	(30.98)	(270.43)	(30.98)
13	Total Comprehensive Income after Tax (11+12)	3,968.70	3,568.02	5,045.85	17,026.03	17,889.31	18,135.84	16,223.67
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	4.68	4.21	5.95	20.07	21.09	21.42	19.14
	(2) Diluted	4.68	4.21	5.95	20.07	21.09	21.42	19.14

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 23, 2017.
- The financial results for the quarter and year ended on March 31, 2017 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016. (Transition date April 1, 2015)
- The reconciliation between net profit for the quarter and year ended March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS as well as the reconciliation of equity for year ended on March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

(Rs. in lakhs)

Particulars	Profit Reconciliation		Reconciliation of Equity
	Quarter ended March 31, 2016	Year ended on March 31, 2016	As At March 31, 2016
Other Equity as per previous Indian GAAP	-	-	1,12,478.57
Net profit reported for March 2016 as per previous Indian GAAP	4,322.91	17,638.85	-
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.85	47.38	-
Net gain/(loss) arising on fair valuation of Investments	1,083.30	268.27	9,861.77
Net gain/(loss) arising on fair valuation of Forward Contracts	(97.00)	43.98	(1.11)
Others	(13.42)	0.11	(0.21)
Deferred Tax Impact on above Adjustments	(254.04)	(78.30)	(2,275.32)
Reversal of Proposed dividend	-	-	510.44
Net Profit/(Loss) after Tax as per Ind AS	5,053.60	17,920.29	-
Other Equity as per Ind AS	-	-	1,20,574.14

- The Company has one reportable segment viz. Pharmaceuticals.
- The Board of Directors has recommended a dividend of Re. 1 per equity share of face value of Rs. 2 (50%).
- The Board of Directors has approved the buy-back of up to 12,50,000 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 1.47% of the total paid up Equity Share capital of the Company) at a price of Rs. 400 per Equity Share for a total consideration not exceeding Rs. 50.00 crores (excluding transaction costs).
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the end of third quarter of the relevant financial year.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

9 The statement of assets and liabilities as on March 31, 2017 is as under:

Particulars	Standalone		Consolidated	
	As at March 31, 2017	As at March 31, 2016	As at March 31, 2017	As at March 31, 2016
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	59,366.61	36,796.94	59,727.03	37,155.25
(b) Capital work-in-progress	376.25	13,418.52	376.25	13,418.52
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	1,502.41	138.45	2,903.39	1,552.73
(e) Intangible assets under development	-	70.48	-	70.48
(f) Financial Assets				
(i) Investments	31,880.88	36,438.23	18,584.20	23,141.55
(ii) Trade receivables	-	-	-	-
(iii) Loans	30.43	15.34	30.43	15.34
(iv) Others	648.77	501.16	648.77	697.16
(g) Other non-current assets	330.76	1,779.63	330.76	1,793.28
TOTAL non current assets	94,136.11	89,158.75	87,914.84	83,158.31
(II) Current assets				
(a) Inventories	15,995.57	13,329.31	20,016.86	18,798.33
(b) Financial Assets				
(i) Investments	22,496.16	24,728.31	22,496.16	24,728.31
(ii) Trade receivables	26,509.52	26,566.79	26,596.62	27,264.17
(iii) Cash and cash equivalents	719.71	1,070.58	1,338.64	1,290.22
(iv) Loans	44.32	56.51	92.61	74.64
(vi) Others	95.57	411.45	114.05	413.39
(c) Other current assets	8,440.31	8,811.79	8,834.07	9,038.65
TOTAL current assets	74,301.16	74,974.73	79,489.02	81,607.71
Total Assets	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,696.40	1,696.40	1,696.40	1,696.40
(b) Other Equity	1,37,089.73	1,20,574.14	1,34,670.51	1,16,687.43
(c) non controlling interest	-	-	218.05	166.50
Total Equity	1,38,786.13	1,22,270.54	1,36,584.96	1,18,550.33
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	888.01	1,020.11	1,256.20	1,043.29
(b) Deferred tax liabilities (Net)	2,895.35	3,206.57	1,046.38	1,677.63
(c) Other non-current liabilities	395.48	380.60	395.48	380.60
TOTAL non current Liabilities	4,178.84	4,607.28	2,698.06	3,101.52
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,886.03	17,440.19	4,886.03	19,302.37
(ii) Trade payables	7,903.47	6,860.93	9,897.71	9,085.09
(iii) Other financial liabilities	10,977.95	11,504.18	11,376.26	13,811.57
(b) Other current liabilities	830.07	398.79	838.44	61.71
(c) Provisions	787.39	622.69	1,035.01	811.79
(d) Current Tax Liabilities (Net)	87.39	428.89	87.39	41.64
TOTAL Current Liabilities	25,472.30	37,255.67	28,120.84	43,114.17
Total Equity and Liabilities	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02

For J.B. Chemicals & Pharmaceuticals Ltd.

J. B. Mody
J. B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 23/05/2017

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

J.K. SHAH & CO.
CHARTERED ACCOUNTANTS

3RD FLOOR, FLAT NO 14,
AL-KARIM MANZIL,
15, PALTON ROAD,
MUMBAI 400 001
TEL. : 2261 5581
2262 0183
e mail: info@jkshah.co.in

Independent Auditors' Report on the Standalone Financial Results of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited
Mumbai, India.

We have audited the accompanying Statement of Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Company") for the year ended 31st March, 2017 ("the Statement"), attached herewith being submitted by the company pursuant to the requirement of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.


This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been compiled from the related Standalone financial statements which have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with the relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.

We have conducted our audit in accordance, with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risk of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedure that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence, we have obtained is sufficient and appropriate to provides a basis for our audit opinion.

In our opinion and to the best of our information and according to the explanations given to us, the Statement;

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No.: CIR/CFD/FAC/62/2016 dated 5th July, 2016; and



J.K. SHAH & CO.
CHARTERED ACCOUNTANTS

3RD FLOOR, FLAT NO 14,
AL-KARIM MANZIL,
15, PALTON ROAD,
MUMBAI 400 001
TEL. : 2261 5581
2262 0183
e mail: info@jkshah.co.in


- ii. give a true and fair view in conformity with the aforesaid Ind AS and other accounting principles generally accepted in India of the net profit, total comprehensive Income and other financial information of the Company for the year ended 31st March, 2017

The Statement includes the results for the Quarter ended 31st March, 2017 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to Limited Review by us.

for J K Shah & Co

Chartered Accountants

Firm's Registration No. : 109606W



J. K. Shah

Partner

Membership No. 3662



Mumbai

23rd May, 2017



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2017


Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2017	31-12-2016	31-03-2016	31-03-2017	31-03-2016	31-03-2017	31-03-2016
		Audited (refer note 7)	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	30,626.19	27,648.17	30,275.91	1,19,869.42	1,16,493.57	1,36,831.70	1,23,158.31
2	Other Income	1,276.27	769.05	2,005.14	4,589.03	5,567.60	5,015.70	5,665.36
3	Total Income (1+2)	31,902.46	28,417.22	32,281.05	1,24,458.45	1,22,061.17	1,41,847.40	1,28,823.67
4	Expenses							
a.	Cost of materials consumed	9,131.39	8,230.94	8,967.58	36,709.36	37,307.84	36,709.36	37,307.84
b.	Purchases of stock-in-trade	2,857.52	2,320.23	2,868.96	9,624.47	8,254.88	15,244.24	11,062.85
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(663.24)	(276.94)	(698.68)	(1,805.26)	(684.05)	843.13	(1,351.43)
d.	Employees benefits expense	4,989.62	4,702.63	4,671.16	18,786.11	16,595.97	20,654.37	17,530.68
e.	Finance Costs	(24.05)	243.00	209.80	500.13	1,029.48	537.16	1,064.59
f.	Depreciation and amortization expense	1,240.46	1,135.96	1,037.31	4,626.42	4,040.87	4,722.44	4,122.23
g.	Other Expenses	9,623.41	8,097.60	8,896.53	34,338.86	32,446.84	40,142.29	38,005.28
	Total Expenses (4)	27,155.11	24,453.42	25,952.66	1,02,780.09	98,991.83	1,18,852.99	1,07,742.04
5	Profit before Tax and share of joint venture (3-4)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,081.63
6	Share of Profit of joint venture	-	-	-	-	-	-	141.47
7	Profit before Tax (5+6)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,223.10
8	Tax expenses	532.44	387.70	1,274.79	4,381.90	5,149.05	4,554.59	4,958.04
9	Net Profit/(Loss) after Tax before non controlling interest(7-8)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,439.82	16,265.05
10	Non controlling interest	-	-	-	-	-	33.55	10.40
11	Net Profit/(Loss) after Tax and non controlling interest (9-10)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,406.27	16,254.65
12	Other Comprehensive Income (net of Tax)	(246.21)	(8.08)	(7.75)	(270.43)	(30.98)	(270.43)	(30.98)
13	Total Comprehensive Income after Tax (11+12)	3,968.70	3,568.02	5,045.85	17,026.03	17,889.31	18,135.84	16,223.67
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
(1) Basic		4.68	4.21	5.95	20.07	21.09	21.42	19.14
(2) Diluted		4.68	4.21	5.95	20.07	21.09	21.42	19.14

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 23, 2017.
- The financial results for the quarter and year ended on March 31, 2017 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016. (Transition date April 1, 2015)
- The reconciliation between net profit for the quarter and year ended March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS as well as the reconciliation of equity for year ended on March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

Particulars	Profit Reconciliation		Reconciliation of Equity
	Quarter ended March 31, 2016	Year ended on March 31, 2016	As At March 31, 2016
Other Equity as per previous Indian GAAP	-	-	1,12,478.57
Net profit reported for March 2016 as per previous Indian GAAP	4,322.91	17,638.85	-
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.85	47.38	-
Net gain/(loss) arising on fair valuation of Investments	1,083.30	268.27	9,861.77
Net gain/(loss) arising on fair Fair valuation of Forward Contracts	(97.00)	43.98	(1.11)
Others	(13.42)	0.11	(0.21)
Deferred Tax Impact on above Adjustments	(254.04)	(78.30)	(2,275.32)
Reversal of Proposed dividend	-	-	510.44
Net Profit/(Loss) after Tax as per Ind AS	5,053.60	17,920.29	-
Other Equity as per Ind AS	-	-	1,20,574.14

- The Company has one reportable segment viz. Pharmaceuticals.
- The Board of Directors has recommended a dividend of Re. 1 per equity share of face value of Rs. 2 (50%).
- The Board of Directors has approved the buy-back of up to 12,50,000 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 1.47% of the total paid up Equity Share capital of the Company) at a price of Rs. 400 per Equity Share for a total consideration not exceeding Rs. 50.00 crores (excluding transaction costs).
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the end of third quarter of the relevant financial year.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED


9 The statement of assets and liabilities as on March 31, 2017 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at March 31, 2017	As at March 31, 2016	As at March 31, 2017	As at March 31, 2016
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	59,366.61	36,796.94	59,727.03	37,155.25
(b) Capital work-in-progress	376.25	13,418.52	376.25	13,418.52
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	1,502.41	138.45	2,903.39	1,552.73
(e) Intangible assets under development	-	70.48	-	70.48
(f) Financial Assets				
(i) Investments	31,880.88	36,438.23	18,584.20	23,141.55
(ii) Trade receivables	-	-	-	-
(iii) Loans	30.43	15.34	30.43	15.34
(iv) Others	648.77	501.16	648.77	697.16
(g) Other non-current assets	330.76	1,779.63	330.76	1,793.28
TOTAL non current assets	94,136.11	89,158.75	87,914.84	83,158.31
(II) Current assets				
(a) Inventories	15,995.57	13,329.31	20,016.86	18,798.33
(b) Financial Assets				
(i) Investments	22,496.16	24,728.31	22,496.16	24,728.31
(ii) Trade receivables	26,509.52	26,566.79	26,596.62	27,264.17
(iii) Cash and cash equivalents	719.71	1,070.58	1,338.64	1,290.22
(iv) Loans	44.32	56.51	92.61	74.64
(v) Others	95.57	411.45	114.05	413.39
(c) Other current assets	8,440.31	8,811.79	8,834.07	9,038.65
TOTAL current assets	74,301.16	74,974.73	79,489.02	81,607.71
Total Assets	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,696.40	1,696.40	1,696.40	1,696.40
(b) Other Equity	1,37,089.73	1,20,574.14	1,34,670.51	1,16,687.43
(c) non controlling interest	-	-	218.05	166.50
Total Equity	1,38,786.13	1,22,270.54	1,36,584.96	1,18,550.33
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	888.01	1,020.11	1,256.20	1,043.29
(b) Deferred tax liabilities (Net)	2,895.35	3,206.57	1,046.38	1,677.63
(c) Other non-current liabilities	395.48	380.60	395.48	380.60
TOTAL non current Liabilities	4,178.84	4,607.28	2,698.06	3,101.52
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,886.03	17,440.19	4,886.03	19,302.37
(ii) Trade payables	7,903.47	6,860.93	9,897.71	9,085.09
(iii) Other financial liabilities	10,977.95	11,504.18	11,376.26	13,811.57
(b) Other current liabilities	830.07	398.79	838.44	61.71
(c) Provisions	787.39	622.69	1,035.01	811.79
(d) Current Tax Liabilities (Net)	87.39	428.89	87.39	41.64
TOTAL Current Liabilities	25,472.30	37,255.67	28,120.84	43,114.17
Total Equity and Liabilities	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02

Place : Mumbai

Date : 23/05/2017



For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
J.B. Mody
Chairman & Managing Director

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380

Independent Auditors' Report on the Consolidated Financial Results of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited
Mumbai, India


1. We have audited the accompanying Statement of Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and Its subsidiaries together referred to as "the Group"), for the year ended 31st March, 2017 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, have been compiled from the related Consolidated financial statements which have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with the relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance, with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risk of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors considers internal control relevant to the Holding Company's preparation and fair presentation of the Statement in order to design audit procedure that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence obtained by us and other auditors in terms of their report referred to in paragraph 4 below is sufficient and appropriate to provides a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial



statements / consolidated financial statement and the other financial information of subsidiaries referred to in paragraph below, the Statement:

- i. Includes the year to date financial results of the following subsidiaries:

List of Subsidiaries:


OOO Unique Pharmaceutical Laboratories,
Unique Pharmaceutical Laboratories FZE and
Biotech Laboratories (Pty.) Ltd (Subsidiary of Unique Pharmaceutical Laboratories FZE)

- ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- iii. give a true and fair view in conformity with the aforesaid Ind AS and other accounting principles generally accepted in India of the consolidated net profit, total comprehensive Income and other financial information of the Group for the year ended 31st March, 2017

4. We did not audit the financial statements / financial information of the subsidiaries referred in paragraph 3(i) above included in the consolidated year to date results, whose financial statements reflect total assets of ₹ 26,140.69 Lakhs as at 31st March, 2017, as well as the total revenue of ₹ 31,373.94 Lakhs for the year ended on that date. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the year to date consolidated financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors.

Our opinion is not modified in respect of above matters with regards to our reliance on the work done and the reports of the other auditors.

for J K Shah & Co
Chartered Accountants
Firm's Registration No. : 109606W



J. K. Shah

Partner

Membership No. 3662

Mumbai

23rd May, 2017





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2017


Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2017	31-12-2016	31-03-2016	31-03-2017	31-03-2016	31-03-2017	31-03-2016
		Audited (refer note 7)	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	30,626.19	27,648.17	30,275.91	1,19,869.42	1,16,493.57	1,36,831.70	1,23,158.31
2	Other Income	1,276.27	769.05	2,005.14	4,589.03	5,567.60	5,015.70	5,665.36
3	Total Income (1+2)	31,902.46	28,417.22	32,281.05	1,24,458.45	1,22,061.17	1,41,847.40	1,28,823.67
4	Expenses							
	a. Cost of materials consumed	9,131.39	8,230.94	8,967.58	36,709.36	37,307.84	36,709.36	37,307.84
	b. Purchases of stock-in-trade	2,857.52	2,320.23	2,868.96	9,624.47	8,254.88	15,244.24	11,062.85
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(663.24)	(276.94)	(698.68)	(1,805.26)	(684.05)	843.13	(1,351.43)
	d. Employees benefits expense	4,989.62	4,702.63	4,671.16	18,786.11	16,595.97	20,654.37	17,530.68
	e. Finance Costs	(24.05)	243.00	209.80	500.13	1,029.48	537.16	1,064.59
	f. Depreciation and amortization expense	1,240.46	1,135.96	1,037.31	4,626.42	4,040.87	4,722.44	4,122.23
	g. Other Expenses	9,623.41	8,097.60	8,896.53	34,338.86	32,446.84	40,142.29	38,005.28
	Total Expenses (4)	27,155.11	24,453.42	25,952.66	1,02,780.09	98,991.83	1,18,852.99	1,07,742.04
5	Profit before Tax and share of joint venture (3-4)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,081.63
6	Share of Profit of joint venture	-	-	-	-	-	-	141.47
7	Profit before Tax (5+6)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,223.10
8	Tax expenses	532.44	387.70	1,274.79	4,381.90	5,149.05	4,554.59	4,958.04
9	Net Profit/(Loss) after Tax before non controlling interest(7-8)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,439.82	16,265.05
10	Non controlling interest	-	-	-	-	-	33.55	10.40
11	Net Profit/(Loss) after Tax and non controlling interest (9-10)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,406.27	16,254.65
12	Other Comprehensive Income (net of Tax)	(246.21)	(8.08)	(7.75)	(270.43)	(30.98)	(270.43)	(30.98)
13	Total Comprehensive Income after Tax (11+12)	3,968.70	3,568.02	5,045.85	17,026.03	17,889.31	18,135.84	16,223.67
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	4.68	4.21	5.95	20.07	21.09	21.42	19.14
	(2) Diluted	4.68	4.21	5.95	20.07	21.09	21.42	19.14

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 23, 2017.
- The financial results for the quarter and year ended on March 31, 2017 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016. (Transition date April 1, 2015)
- The reconciliation between net profit for the quarter and year ended March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS as well as the reconciliation of equity for year ended on March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

Particulars	Profit Reconciliation		Reconciliation of Equity
	Quarter ended March 31, 2016	Year ended on March 31, 2016	As At March 31, 2016
Other Equity as per previous Indian GAAP	-	-	1,12,478.57
Net profit reported for March 2016 as per previous Indian GAAP	4,322.91	17,638.85	-
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.85	47.38	-
Net gain/(loss) arising on fair valuation of Investments	1,083.30	268.27	9,861.77
Net gain/(loss) arising on fair Fair valuation of Forward Contracts	(97.00)	43.98	(1.11)
Others	(13.42)	0.11	(0.21)
Deferred Tax Impact on above Adjustments	(254.04)	(78.30)	(2,275.32)
Reversal of Proposed dividend	-	-	510.44
Net Profit/(Loss) after Tax as per Ind AS	5,053.60	17,920.29	-
Other Equity as per Ind AS	-	-	1,20,574.14

- The Company has one reportable segment viz. Pharmaceuticals.
- The Board of Directors has recommended a dividend of Re. 1 per equity share of face value of Rs. 2 (50%).
- The Board of Directors has approved the buy-back of up to 12,50,000 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 1.47% of the total paid up Equity Share capital of the Company) at a price of Rs. 400 per Equity Share for a total consideration not exceeding Rs. 50.00 crores (excluding transaction costs).
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the end of third quarter of the relevant financial year.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED


9 The statement of assets and liabilities as on March 31, 2017 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at March 31, 2017	As at March 31, 2016	As at March 31, 2017	As at March 31, 2016
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	59,366.61	36,796.94	59,727.03	37,155.25
(b) Capital work-in-progress	376.25	13,418.52	376.25	13,418.52
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	1,502.41	138.45	2,903.39	1,552.73
(e) Intangible assets under development	-	70.48	-	70.48
(f) Financial Assets				
(i) Investments	31,880.88	36,438.23	18,584.20	23,141.55
(ii) Trade receivables	-	-	-	-
(iii) Loans	30.43	15.34	30.43	15.34
(iv) Others	648.77	501.16	648.77	697.16
(g) Other non-current assets	330.76	1,779.63	330.76	1,793.28
TOTAL non current assets	94,136.11	89,158.75	87,914.84	83,158.31
(II) Current assets				
(a) Inventories	15,995.57	13,329.31	20,016.86	18,798.33
(b) Financial Assets				
(i) Investments	22,496.16	24,728.31	22,496.16	24,728.31
(ii) Trade receivables	26,509.52	26,566.79	26,596.62	27,264.17
(iii) Cash and cash equivalents	719.71	1,070.58	1,338.64	1,290.22
(iv) Loans	44.32	56.51	92.61	74.64
(v) Others	95.57	411.45	114.05	413.39
(c) Other current assets	8,440.31	8,811.79	8,834.07	9,038.65
TOTAL current assets	74,301.16	74,974.73	79,489.02	81,607.71
Total Assets	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,696.40	1,696.40	1,696.40	1,696.40
(b) Other Equity	1,37,089.73	1,20,574.14	1,34,670.51	1,16,687.43
(c) non controlling interest	-	-	218.05	166.50
Total Equity	1,38,786.13	1,22,270.54	1,36,584.96	1,18,550.33
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	888.01	1,020.11	1,256.20	1,043.29
(b) Deferred tax liabilities (Net)	2,895.35	3,206.57	1,046.38	1,677.63
(c) Other non-current liabilities	395.48	380.60	395.48	380.60
TOTAL non current Liabilities	4,178.84	4,607.28	2,698.06	3,101.52
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,886.03	17,440.19	4,886.03	19,302.37
(ii) Trade payables	7,903.47	6,860.93	9,897.71	9,085.09
(iii) Other financial liabilities	10,977.95	11,504.18	11,376.26	13,811.57
(b) Other current liabilities	830.07	398.79	838.44	61.71
(c) Provisions	787.39	622.69	1,035.01	811.79
(d) Current Tax Liabilities (Net)	87.39	428.89	87.39	41.64
TOTAL Current Liabilities	25,472.30	37,255.67	28,120.84	43,114.17
Total Equity and Liabilities	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02

Place : Mumbai

Date : 23/05/2017



For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
J.B. Mody
Chairman & Managing Director

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380